In this randomised , double-blind , placebo-controlled , parallel-group , phase 3 trial done in 25 hospitals in mainland China , Hong Kong , South Korea , Taiwan , and Vietnam , we recruited Asian patients aged 18 years or older with progressive metastatic colorectal cancer who had received at least two previous treatment lines or were unable to tolerate standard treatments .